Diagnosis Articles

?️ Articles on positive diagnosis of NASH/NAFLD; there should be hepatic steatosis by imaging or histology or no significant alcohol consumption.

NAFLD in the elderly

Authors: Alqahtani SA, Schattenberg JM.
Published in Clin Interv Aging 2021
The diagnosis and management strategies of NAFLD in older adults are sometimes challenging, and certain age-specific factors have to be taken into account. In this review, S. A. Alqahtani (King Faisal Specialist Hospital & Research Center, Saudi Arabia and Johns...
Read More

FIB-4 and NFS: which performance?

Authors: Castellana M, Donghia R, Guerra V, et al.
Published in Am J Gastroenterol 2021
M. Castellana et al. (National Institute of Gastroenterology "Saverio de Bellis," Research Hospital, Italy) conducted a meta-analysis to assess the performance of the FIB-4 and NFS scores, the 2 most common non-invasive tools, for the appropriate selection of subjects with AF for biopsy. A total of 18 studies evaluating 12,604 subjects were included...
Read More

Enhanced liver fibrosis test and recognition of liver fibrosis

Authors: Younossi ZM, Felix S, Jeffers T, et al.
Published in JAMA Netw Open 2021
This retrospective cross-sectional study was conducted among patients recruited from a large, community-based hospital system's outpatient liver clinic from 2001 to 202 in order to determine the performance of the enhanced liver fibrosis (ELF) test as a non-invasive test for assessment of liver fibrosis among patients with NAFLD...
Read More

NAFLD unawareness in US adults

Authors: Alqahtani SA, Paik JM, Biswas R, et al.
Published in Mol Metab 2021
MAFLD is closely related to disturbances in systemic energy metabolism, including insulin resistance and atherogenic dyslipidaemia. This review by J. Heeren and L Scheja (University Medical Center Hamburg-Eppendorf, Germany) discusses recent research addressing lipoprotein metabolism in the context of MAFLD...
Read More

Identifying patients with high-risk NASH: three ultrasound markers

Authors: Sugimoto K, Lee DH, Lee JY, et al.
Published in Radiology 2021
Identifying patients with high-risk-NASH who are candidates for pharmacologic therapy remains a challenge. K. Sugimoto et al. (Tokyo Medical University, Japan) aimed to develop a score to identify patients with a NAFLD activity score of 4 or greater and clinically significant fibrosis...
Read More

Detection of HCC in patients with NAFLD

Authors: Caviglia GP, Armandi A, Rosso C, et al.
Published in Cancers (Basel) 2021
Current surveillance strategy for patients with NAFLD at risk of HCC development is unsatisfactory. G. P. Caviglia et al. (National University Health System, and Yong Loo Lin School of Medicine, National University of Singapore) aimed to investigate the diagnostic accuracy of alpha-fetoprotein (AFP), protein induced by vitamin K...
Read More

NAFLD: no liver biopsy in 2/3 patients of a real-world cohort

Authors: Barritt AS, Watkins S, Gitlin N, et al.
Published in Hepatol Commun 2021
Much of the current data on NAFLD are derived from biopsy-based studies that may introduce ascertainment and selection bias. Selection of patients for liver biopsy has implications for clinical practice and the reported epidemiology of NAFLD. The aim of this study was to determine patient factors predictive....
Read More

NAFLD in patients with schizophrenia: early detection should be conducted

Authors: Koreki A, Mori H, Nozaki S, et al.
Published in J Clin Psychopharmacol 2021
ndividuals with schizophrenia have high levels of medical comorbidity and cardiovascular risk factors. Patients with schizophrenia should receive regular monitoring and adequate treatment of cardio-metabolic risk factors. Nevertheless, little is known regarding NAFLD in patients with schizophrenia. A. Koreki et al. analysed the medical...
Read More

Assessment of imaging modalities against liver biopsy

Authors: Troelstra MA, Witjes JJ, van Dijk AM, et al.
Published in J Magn Reson Imaging 2021
Multiparametric MRI is a promising technique to assess hepatic steatosis, inflammation, and fibrosis, potentially enabling non-invasive identification of individuals with active and advanced stages of NAFLD. The aim of the current proof-of-principle study by M. A. Troelstra et al. (Amsterdam University Medical Centres, The ...
Read More

NAFLD: a year in review

Authors: Abdelmalek MF.
Published in Nat Rev Gastroenterol Hepatol 2021
he field of NAFLD and its progressive form, NASH, has, despite the challenges of the COVID-19 pandemic, continued to rapidly evolve in 2020. There have been substantial advances in NAFLD mechanisms, diagnostics, and treatment. Key developments include the identification of a multiparametric cellular and tissue signature to define disease progression...
Read More

Cost-effectiveness of screening for NAFLD in patients with T2D

Authors: Noureddin M, Jones C, Alkhouri N, et al.
Published in Gastroenterology 2020
The authors hypothesized that screening for NAFLD in type 2 diabetes (T2D) patients, starting with ultrasound (US) and alanine aminotransferase (ALT) or aspartate aminotransferase (AST), followed with non-invasive testing for fibrosis to detect those most likely to have fibrosis stage ≥F2, is more cost effective than not screening this population...
Read More